^
    Back
    Association details:
    Biomarker:IDH1 mutation
    Cancer:Glioblastoma
    Drug:Keytruda (pembrolizumab) (PD1 inhibitor)
    Direction:Resistant
    Evidence:
    Evidence Level:
    Resistant: C3 – Early Trials
    Source:
    Clin Cancer Res
    Title:

    Randomized phase II and biomarker study of pembrolizumab plus bevacizumab versus pembrolizumab alone for recurrent glioblastoma patients

    Published date:
    11/16/2020
    Excerpt:
    Eighty bevacizumab-naive, recurrent glioblastoma patients randomized to pembrolizumab with bevacizumab (cohort A, n=50) or pembrolizumab monotherapy (cohort B, n=30)….worsened OS correlated with baseline dexamethasone use and increased post-therapy plasma VEGF (cohort A) and mutant IDH1, unmethylated MGMT and increased baseline PlGF and sVEGFR1 levels (cohort B).
    DOI:
    10.1158/1078-0432.CCR-20-2500